Pamidronate    (DrugBank: Pamidronate)

2 diseases
IDDisease name (Link within this page)Number of trials
271Ankylosing spondylitis1
274Osteogenesis Imperfecta6

271. Ankylosing spondylitis    [ 531 clinical trials,   343 drugs,   (DrugBank: 66 drugs),   41 drug target genes,   141 drug target pathways]
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 531 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02313727
(ClinicalTrials.gov)
December 20141/12/2014Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic ProgressionCombined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic ProgressionAnkylosing SpondylitisDrug: Pamidronate;Other: Placebo (NaCl 0.9%)Bnai Zion Medical CenterJanssen-Cilag Ltd.Not yet recruiting18 YearsN/AMale30Phase 4Israel

274. Osteogenesis Imperfecta    [ 78 clinical trials,   87 drugs,   (DrugBank: 19 drugs),   14 drug target genes,   74 drug target pathways]
Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 78 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000031290
2018/05/3001/04/2018Efficacy of pamidronate for adult osteogenesis imperfecta: uncontrolled study.Efficacy of pamidronate for adult osteogenesis imperfecta: uncontrolled study. - Efficacy of pamidronate for adult osteogenesis imperfecta Osteogenesis imperfectaPamidronate disodium intervenous for drip use; 15mg/day (available up to 30mg/day), 1 infection/day x 3 dats, every 4 months, total 16 months.Kobe University HospitalNULLRecruiting20years-oldNot applicableMale and Female10Not applicableJapan
2EUCTR2016-003228-22-GB
(EUCTR)
14/12/201619/10/2016Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acidTreatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid - TOPaZ study Osteogenesis imperfecta
MedDRA version: 20.0;Level: PT;Classification code 10031243;Term: Osteogenesis imperfecta;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
Trade Name: Teriparatide
Product Name: Teriparatide
Trade Name: Zoledronic acid
Product Name: Zoledronic acid
Trade Name: Alendronic acid
Product Name: Alendronic acid
Trade Name: Risedronate sodium
Product Name: Risedronate sodium
Trade Name: Ibandronic acid
Product Name: Ibandronic acid
Trade Name: Ibandronic acid
Product Name: Ibandronic acid
Trade Name: Disodium Pamidronate 15mg (15mg strength)
Product Name: Disodium Pamidronate 15mg (15mg strength)
Trade Name: Prolia
Product Name: Prolia
Trade Name: Bonefos
Product Name: Bonefos
University of EdinburghNHS LothianAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
380Phase 4Ireland;United Kingdom
3NCT00655681
(ClinicalTrials.gov)
September 20074/4/2008Prevention of Post Operative Bone Loss in ChildrenPrevention of Post Operative Bone Loss in ChildrenOsteoporosis;Cerebral Palsy;Spina Bifida;Osteopenia;Osteogenesis ImperfectaDrug: pamidronate;Other: salineUniversity of New MexicoThrasher Research FundCompleted4 Years18 YearsBoth24N/AUnited States
4NCT00005901
(ClinicalTrials.gov)
June 20006/6/2000Pamidronate to Treat Osteogenesis Imperfecta in ChildrenA Trial of Pamidronate in Children With Osteogenesis ImperfectaOsteogenesis ImperfectaDrug: Pamidronate (Aredia)Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)National Institutes of Health Clinical Center (CC)CompletedN/A16 YearsAll34Phase 3United States;Canada
5NCT00159419
(ClinicalTrials.gov)
August 19997/9/2005Bisphosphonate Therapy for Osteogenesis ImperfectaBisphosphonate Therapy for Osteogenesis ImperfectaOsteogenesis Imperfecta;Osteoporosis;Paget Disease of BoneDrug: Alendronate;Drug: PamidronateIndiana University School of MedicineNULLCompleted3 Years21 YearsAll18Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2015-003539-37-Outside-EU/EEA
(EUCTR)
07/03/2016Bisphosphonate Treatment of Osteogenesis ImperfectaAn international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis imperfect. Osteogenesis Imperfecta;Therapeutic area: Diseases [C] - Cancer [C04]Trade Name: ZometaNovartisNULLNAFemale: yes
Male: yes
158United States